Insiders

Gilead Sciences Chief Medical Officer to Step Down

July 17, 2024 at 09:21 am

By Michael Susin

Gilead Sciences on Wednesday said its Chief Medical Officer Merdad Parsey will leave the company early next year.

The biopharmaceutical company said Parsey will continue in the role until the first quarter of 2025 and support this transition over the next several months.

Parsey joined the Gilead in November 2019 and is responsible for overseeing the company's global clinical development and medical affairs organizations.

Write to Michael Susin at michael.susin@wsj.com

(END) Dow Jones Newswires

07-17-24 0919ET

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	GILEAD SCIENCES, INC.	72.18 USD	+0.76%	+5.45%	89.25B

Merdad Parsey

Dr. Merdad V. Parsey is an Independent Director at Arcus Biosciences, Inc. and a Chief Medical Officer at Gilead Sciences, Inc. He is on the Board of Directors at Arcus Biosciences, Inc. and Sagimet Biosciences, Inc. Dr. Parsey was previously employed as a Senior Medical Director by Regeneron Pharmaceuticals, Inc., a Senior Director-Medical Group by Genentech, Inc., an Associate Medical Director by Merck & Co., Inc., a Director-Critical Care Medicine by New York University School of Medicine, a Member by Roche Group, and a Senior Medical Director by Sunovion Pharmaceuticals, Inc. He received his doctorate degree from the University of Maryland.

View full profile